Hardman & Co Research: Diurnal Group (DNL): First commercial revenues

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Diurnal Group (DNL): First commercial revenues 
 
04-Oct-2018 / 17:10 GMT/BST 
 
*Hardman & Co: First commercial revenues* 
 
Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused 
on diseases of the endocrine system. Its two lead products target rare 
conditions where medical needs are currently unmet, with the aim of building a 
long-term 'Adrenal Franchise'. Following approval from the European 
Commission, Alkindi is being launched in key EU markets through DNL's own 
commercial infrastructure, starting with Germany and now launched in the UK. 
Additional territories will follow during 2018 and 2019. Meanwhile, the 
company is pushing forward with Alkindi and Chronocort clinical trials in the 
US. Cash at the end of the period was GBP17.3m. 
 
Please click here for the full report: 
 
http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents 
/04.10.18-first-commercial-revenues.pdf [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
730409 04-Oct-2018 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=28893b21df9a4ea33c5cc4c550cd7082&application_id=730409&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=730409&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

October 04, 2018 12:10 ET (16:10 GMT)